ArticleAnnals of maxillofacial surgery
Expression of CD24 as Cancer Stem Cell Marker in the Diagnosis of Oral Squamous Cell Carcinoma - A Prospective Study.
Article in Annals of maxillofacial surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas.Journal of dental sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral squamous cell carcinoma (OSCC) is an aggressive and recurrent malignancy. Identification of unique and overexpressed cell surface antigens is important in the diagnosis and development of cancer vaccines and various therapies for OSCC. We have used real-time polymerase chain reaction (RT-PCR) for the expression of cell surface protein CD24 in both tissue samples and in blood samples to study the clinicopathological features as well as to determine the gene expression profile of CD24 in OSCC and explore its role as a potential target of clinical therapy. Materials and Methods: In this prospective study, the expression of CD24 was evaluated in 20 blood (3 ml) and tissue samples of OSCC specimens by quantitative RT-PCR. Student's Results: CD24 was found to be upregulated amongst the cases for both the tissue and the blood. CD24 was statistically significant with Discussion: CD24 expression is significantly upregulated in blood and tissue samples in OSCC. In addition, CD24 overexpression is highly associated with adverse prognostic parameters such as lymph node involvement, advanced clinical stages and worse overall survival. Our findings have important implications in future practice, overexpression of CD24 in OSCC was associated with poor prognosis correlating to the clinical findings, large-scale comprehensive studies are needed further to confirm our findings. In addition to histological features, CD24 can be used as marker for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.